Xylazine

Overview

Xylazine is a structural analog of clonidine and an α₂-adrenergic receptor agonist, sold under many trade names worldwide, most notably the Bayer brand name Rompun, as well as Anased, Sedazine and Chanazine.[1][2][3] WP

Xylazine is a common veterinary drug used for sedation, anesthesia, muscle relaxation, and analgesia in animals such as horses, cattle, and other mammals. In veterinary anesthesia, it is often used in combination with ketamine. Veterinarians also use xylazine as an emetic, especially in cats. Drug interactions vary with different animals.[2][4–7] WP

Xylazine was first investigated for human use in the 1960s in West Germany for antihypertensive effects before being discontinued and marketed as a veterinary sedative. Xylazine's mechanism of action was discovered in 1981, which led to the creation of other α₂-adrenergic receptor agonists such as medetomidine and dexmedetomidine. WP

Xylazine has become a commonly abused street drug in the United States where it is known by the street name "tranq", particularly in the territory of Puerto Rico. The drug is used as a cutting agent for heroin and fentanyl.[8–12] WP

Drug class

α2-Adrenergic receptor agonist Sedative Anesthetic Emetic WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Veterinary use

Xylazine is widely used in veterinary medicine as a sedative, muscle relaxant, and analgesic. It is frequently used in the treatment of tetanus. It is not used in human medical treatment. Xylazine is similar to drugs such as phenothiazines, tricyclic antidepressants, and clonidine. As an anesthetic, it is typically used in conjunction with ketamine. In animals, xylazine may be administered intramuscularly, intravenously, and intraosseously. Subcutaneous, oral transmusocal and intranasal have been investigated but are not standard routes for xylazine administration. As a veterinary anesthetic, xylazine is typically only administered once for the intended effect before or during surgical procedures. α₂-Adrenergic receptor antagonists such as atipamezole and yohimbine may be used to reverse the effects of xylazine in animals. Xylazine is licensed for use in non-meat horses. Off-label use in cattle is common with recommended withholding periods of 1–5 days for dairy cattle and 4–10 days for meat cattle. Cattle are more sensitive to xylazine than horses with the sensitivity being greater in meat cattle breeds than dairy cattle breeds.[1][3][13–17] WP

Xylazine's use in cats and dogs is being replaced with the more selective alpha₂ adrenergic receptor agonists medetomidine and dexmedetomidine and in some countries xylazine is rarely used with cats and dogs.[14] WP

High amounts of catecholamines in a patient will require higher doses of xylazine to be administered to provide sedation. The heightened levels required may not be practical or possible to administer and regular doses may cause excitement.[14] WP

Recreational use

In 1979, the first case of xylazine toxicity was reported in a 34-year-old male who had self-medicated for insomnia with an injection of 1g of xylazine.[18] WP

In the US, Xylazine is not regulated as a controlled substance under the Controlled Substances Act. It is sold online through distributors often without requiring proof of a veterinary license. The cost to purchase Xylazine from overseas suppliers is around $6–20 per kilogram. This low price makes it attractive for dealers looking for a cheap additive that is addictive and not treatable with opiate withdrawal medications. The withdrawal can last for two weeks and has a quicker onset than fentanyl.[19][20][21] WP

As an adulterant, xylazine is most commonly ingested with fentanyl. Xylazine has also been reported in combination with medetomidine, another potent α₂-adrenergic receptor agonist. It is unknown if drug users are ingesting it knowingly. As of 2024, Seattle police report that some users wrongly believe they are consuming higher-quality fentanyl. Xylazine's street name in Puerto Rico is anestesia de caballo, which translates to "horse anesthetic". From 2002 to 2008, its use was associated with a high number of inmate deaths at the Guerrero Correctional Institution in Aguadilla, Puerto Rico.[3][22–29] WP

Xylazine's street name in the United States, particularly when it is mixed with medetomidine and/or fentanyl, is "tranq", "tranq dope" and "zombie drug".[30][31] WP

As of 2012, xylazine users in Puerto Rico were more likely to be male, under age 30, living in a rural area, and injecting rather than inhaling xylazine. The combination of heroin and xylazine produces a potentially more deadly high than heroin alone. Xylazine is also frequently found in "speedball", a mixture of a stimulant drug such as cocaine with a depressant drug such as heroin, morphine and/or fentanyl. As of 2012, causal factors underlying xylazine's increasing popularity were still unknown.[12][28] WP

As of 2022, more information on the distribution of xylazine in the body, physical symptoms, and factors predictive of chronic use was known: frequency of use depended on social or economic factors, as well as each user's subjective response to the drug's addictive properties. From November 2021 until August 2022, 80% of drug paraphernalia which tested positive for fentanyl at needle exchange programs in Maryland also contained xylazine. As of 2022, xylazine was almost invariably combined with opioids when used recreationally, and the drug produced a characteristic withdrawal syndrome which complicates treatment of addicted users.[32–35] WP

In April 2023, the Biden administration declared xylazine-laced fentanyl an official emerging drug threat to the nation, the first time such a label has been given. In 2022, the Drug Enforcement Administration (DEA) reported that 23% of seized fentanyl powder and 7% of fentanyl pills were found to have been adulterated with xylazine.[8][36] WP

In July 2023, the first death following xylazine use outside of North America was reported to have taken place in Solihull, England on May 22. A 43-year-old male was found dead at home with postmortem toxicology detecting heroin, cocaine, fentanyl and xylazine.[37] WP

Risks and side effects

Side effects

Side effects in animals include transient hypertension and hypotension. Xylazine decreases both respiration rate and minute ventilation, although the changes to PaCO₂ and PaO₂ are minor and innocuous.[3][14] WP

Xylazine has been demonstrated to reduce the dose of epinephrine that causes arrythmia in dogs anaesthetised with isoflurane and halothane.[14][38][39] WP

Xylazine administration in sheep activates pulmonary macrophages that damage the capillary endothelium and alveolar type I cells. This in turns causes alveolar haemorrhage and oedema causing hypoxaemia.[14][40][41] WP

Intracarotid administration can cause seizures and excitement in horses.[14] WP

Xylazine has been shown to cause myometrial contractions in pregnant cattle. Further evidence of xylazine's effect on pregnant animals is lacking and although other a₂ adrenergic receptor agonists have been shown to not cause the same myometrial contraction the administration of a₂ adrenergic receptor agonists is not recommended and for animals near-term should only be used in specific circumstances.[14][42] WP

Xylazine affects the glucose level via the activation of alpha2A andrenergic receptors on beta cells, which prevents insulin release. alpha₂ adrenergic receptors have been reported to cause transient hyperglycaemia with xylazine being reported as a cause in cattle and equine. The renal threshold for glucose is not exceeded due to the hyperglycaemia with clinical doses. An alpha₂ adrenergic receptor antagonist can reverse the effect.[14][43][44] WP

Emesis is the most common side effect in small animals; however, this can be a desired effect and xylazine is often used as an emetic in cats.[45] WP

Side effects

Xylazine overdose is often fatal in humans. Because it is used as a drug adulterant, the symptoms caused by the drugs accompanying xylazine administration vary between individuals.[1][12] WP

The most common side-effects in humans associated with xylazine administration include bradycardia, respiratory depression, hypotension, transient hypertension secondary to α₁-adrenergic receptor stimulation, and other central and hemodynamic changes. Xylazine significantly decreases heart rate in animals that are not pre-medicated with medications that have anticholinergic effects.[1][12][46] WP

Symptoms that can occur following overdose are areflexia, asthenia, ataxia, blurred vision, disorientation, dizziness, dysarthria, dysmetria, fainting, hyporeflexia, somnolence, coma, apnea, premature ventricular contraction, tachycardia, miosis, and hyperglycaemia. Rarely, hypotonia, urinary incontinence, and nonspecific electrocardiographic ST segment changes occur. Following a human overdose, symptoms can last for 8–72 hours, varying based on xylazine's combined usage with other drugs.[1][3] WP

Overdose

Human tolerance to xylazine varies widely, with toxicity and fatality occurring between doses of 40–2400 mg. Non-fatal blood or plasma concentration ranges from 0.03 to 4.6 mg/L. In fatalities, the blood concentration of xylazine ranges from trace to 16 mg/L. It is reported that there is no defined safe or fatal concentration of xylazine because of the significant overlap between the non-fatal and postmortem blood concentrations of xylazine.[3][47] WP⚠ The source also gives this in other units.

Hemodialysis has been suggested as a form of treatment, but is usually unfavorable due to the large volume of distribution of xylazine.[3] WP

There are no standardized screenings to determine if an overdose has occurred. Detection of xylazine in humans involves various screening methods, such as urine screenings, thin layer chromatography (TLC), gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–mass spectrometry (LC-MS). As of November 2022, detecting xylazine in a drug sample requires spectrophotometry.[27][47][48] WP

As of 1998, the α₂-adrenergic receptor antagonist atipamezole was used to reverse the effects of xylazine or the related drug dexmedetomidine in veterinary medicine, but this is not an approved medical treatment for humans, despite Phase I clinical trials in 2005.[49][50] WP

As of 2001, the effects of xylazine in animals were also reversed by the analeptics 4-aminopyridine, doxapram, and caffeine, which are physiological antagonists to central nervous system depressants. The ways to accurately identify chronic xylazine use are unknown, and the effective treatments, if any, are not standardized. As of 2014, multiple drugs have been used for therapeutic intervention, including lidocaine, naloxone, thiamine, lorazepam, vecuronium, etomidate, propofol, tolazoline, yohimbine, atropine, orciprenaline, metoclopramide, ranitidine, metoprolol, enoxaparin, flucloxacillin, insulin, and irrigation of both eyes with saline.[1][3][51][52] WP

The treatment after a xylazine overdose primarily involves maintaining respiratory function and blood pressure. In cases of intoxication, physicians recommend intravenous fluid infusion, atropine, and hospital observation. Severe cases may require tracheal intubation, mechanical ventilation, gastric lavage, activated charcoal, bladder catheterization, electrocardiographic (ECG) and hyperglycemia monitoring. Physicians typically recommend which detoxification treatment should be used to manage possible dysfunction involving highly perfused organs such as the liver and kidneys.[1][3][47] WP

Pharmacology

Pharmacodynamics

Xylazine is a potent α₂-adrenergic receptor agonist. When xylazine and other α₂-adrenergic receptor agonists are administered, they distribute throughout the body within 30 to 40 minutes. Due to xylazine's highly lipophilic nature, it directly stimulates central α₂-adrenergic receptors as well as peripheral α-adrenergic receptors in a variety of tissues. As an agonist, xylazine reduces release of norepinephrine in the central nervous system. It does so by mimicking norepinephrine in binding to the pre-synaptic surface autoreceptors, which leads to feedback inhibition of norepinephrine release. Recent data suggests that xylazine treatment can induce dopamine release in the nucleus accumbens through an unresolved mechanism, and this effect is blocked by atipamezole.[1][3][14][53–56] WP

Xylazine also serves as a transport inhibitor by suppressing norepinephrine transport function through competitive inhibition of substrate transport. Accordingly, xylazine significantly increases Kₘ and does not affect Vₘₐₓ. This likely occurs by direct interaction on an area that overlaps with the antidepressant binding site. For example, xylazine and clonidine suppress uptake of iobenguane (MIBG), a norepinephrine analogue, in neuroblastoma cells. Xylazine's chemical structure closely resembles clonidine.[55] WP

It has also been reported that xylazine activates the κ-opioid receptors, with low potency, which may contribute to its effects.[57] WP

Unlike other α₂-adrenergic receptor agonists xylazine does not have any imidazoline receptor activity. Xylazine binds at a ratio of 160:0, the lowest of all α₂-adrenergic receptor agonists and 1/10th of that of medetomidine and dexmedotimidine.[14] WP

Xylazine is less selective than the other α₂-Adrenergic receptor agonists.[14] WP

The analgesic effect of xylazine comes from binding to receptors at the substantia gelatinosa and locus coeruleus.[14] WP

In animals

In dogs, sheep, horses, and cattle, the half-life is very short: only 1–6 minutes. Complete elimination of the drug can take up to 23 minutes in sheep and up to 49 minutes in horses. In young rats the half-life is one hour. Xylazine has a large volume of distribution of Vd = 1.9–2.5 for horses, cattle, sheep, and dogs. Though the peak plasma concentrations are reached in 12–14 minutes in all species, the bioavailability varies between species. The half-life depends on the age of the animal, as age is related to prolonged duration of anesthesia and recovery time. Toxicity occurs with repeated administration, given that the metabolic clearance of the drug is usually calculated as 7–9 times the half-life, which is 4 to 5 days for the clearance of xylazine.[1][3][58] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

In humans

Xylazine is absorbed, metabolized, and eliminated rapidly. It can be inhaled or administered intravenously, intramuscularly, subcutaneously, or orally either by itself or in conjunction with other anesthetics, such as ketamine, barbiturates, chloral hydrate, and halothane in order to provide reliable anesthesia effects. The most common route of administration is injection.[12][13] WP

Xylazine's action can be seen usually 15–30 minutes after administration and the sedative effect may continue for 1–2 hours and last up to 4 hours. Once xylazine gains access to the vascular system, it is distributed within the blood, allowing it to enter the heart, lungs, liver, and kidneys. In non-fatal cases, the blood plasma concentrations range from 0.03 to 4.6 mg/L. Xylazine diffuses extensively and penetrates the blood–brain barrier, since the molecule does not have a charge and dissolves in lipids.[3][47] WP

Xylazine is metabolized by the liver's cytochrome P450 enzymes. When it reaches the liver, xylazine is metabolized and proceeds to the kidneys to be excreted in urine. Around 70% of a dose is excreted unchanged. Thus, urine can be used in detecting xylazine administration because it contains many metabolites, which are the main targets and products in urine. Within a few hours, xylazine decreases to undetectable levels. Other factors can also significantly impact the pharmacokinetics of xylazine, such as sex, nutrition, environmental conditions, and prior diseases.[1][3][27][58][59] WP⚠ A table follows this text in the source and is not copied here. Open the source to see it.

History

History

Xylazine was discovered as an antihypertensive agent in 1962 by Farbenfabriken Bayer in Leverkusen, West Germany. In human trials xylazine was found to depress the central nervous system leading to the discontinuation of further research for its use in humans and it was instead marketed as a veterinary sedative, starting in the late 1960s. Xylazine proved popular and in the 1970s became one of the most common large animal sedatives. Xylazine's muscle relaxant effect inhibits the transmission of neural impulses in the central nervous system. In 1981 a study discovered that the cause sedation was due to xylazine's effect on the α2-adrenergic receptor. This led to the development of other α₂-adrenergic receptor agonists such as detomidine, medetomidine, dexmedetomidine, and romifidine.[1][14][53][54] WP

In the United States, xylazine was approved by the FDA only for veterinary use as a sedative, analgesic, and muscle relaxant in dogs, cats, horses, elk, fallow deer, mule deer, sika deer, and white-tailed deer.[1][3] WP

In scientific research using animal experiments, xylazine is a component of the most common anesthetic, ketamine-xylazine, to anesthetize rats, mice, hamsters, and guinea pigs.[58] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Xylazine has not previously been a controlled substance; however, due to illicit abuse, legislative restrictions have been proposed in multiple countries. Xylazine was made a class C drug in the UK on 15 January 2025.[14][60][61] WP

Chemistry

Formula

C12H16N2S PC

CAS number

7361-61-7 PC

Molar mass (g/mol)

220.34 PC

IUPAC name (computed by PubChem)

N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine PC

SMILES

CC1=C(C(=CC=C1)C)NC2=NCCCS2 PC

InChIKey

BPICBUSOMSTKRF-UHFFFAOYSA-N PC

PubChem CID

5707

IUPAC name

N-(2,6-Dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Greene SA, Thurmon JC. Xylazine–a review of its pharmacology and use in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics. December 1988. doi:10.1111/j.1365-2885.1988.tb00189.x · PMID 3062194
2. Other Xylazine
3. Journal / agency Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, Martínez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature. Forensic Science International. July 2014. doi:10.1016/j.forsciint.2014.03.015 · PMID 24769343
4. Other Dowling PM. Merck Veterinary Manual. June 2016
5. Journal / agency Haskins SC, Patz JD, Farver TB. Xylazine and xylazine-ketamine in dogs. American Journal of Veterinary Research. March 1986. doi:10.2460/ajvr.1986.47.03.636 · PMID 3963565
6. Journal / agency Muir WW, Skarda RT, Milne DW. Evaluation of xylazine and ketamine hydrochloride for anesthesia in horses. American Journal of Veterinary Research. February 1977. doi:10.2460/ajvr.1977.38.02.195 · PMID 842917
7. Journal / agency Aithal HP, Pratap AK, Singh GR. Clinical effects of epidurally administered ketamine and xylazine in goats. Small Ruminant Research. 1997. doi:10.1016/s0921-4488(96)00919-4
8. Other DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine. 2023-03-21
9. Other Recommendations for Caring for Individuals with Xylazine-Associated Wounds
10. Other Quynh J. Feds target Chinese based fentanyl supply chain with ties to Florida. October 4, 2023
11. Other Rowland B. Justice Department goes after China-based companies in fentanyl fight. October 3, 2023
12. Journal / agency Reyes JC, Negrón JL, Colón HM, Padilla AM, Millán MY, Matos TD, Robles RR. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. Journal of Urban Health. June 2012. doi:10.1007/s11524-011-9662-6 · PMID 22391983 · PMC3368046
13. Journal / agency Xiao YF, Wang B, Wang X, Du F, Benzinou M, Wang YX. Xylazine-induced reduction of tissue sensitivity to insulin leads to acute hyperglycemia in diabetic and normoglycemic monkeys. BMC Anesthesiology. October 2013. doi:10.1186/1471-2253-13-33 · PMID 24138083 · PMC4016475
14. Other Lamont LA, Creighton CM. Veterinary Anesthesia and Analgesia, The 6th Edition of Lumb and Jones. 11 September 2024
15. Journal / agency Kollias-Baker CA, Court MH, Williams LL. Influence of yohimbine and tolazoline on the cardiovascular, respiratory, and sedative effects of xylazine in the horse. Journal of Veterinary Pharmacology and Therapeutics. September 1993. doi:10.1111/j.1365-2885.1993.tb00182.x · PMID 8230406
16. Journal / agency Murahata Y, Miki Y, Hikasa Y. Antagonistic effects of atipamezole, yohimbine, and prazosin on xylazine-induced diuresis in clinically normal cats. Canadian Journal of Veterinary Research. October 2014. PMID 25356000 · PMC4170770
17. Journal / agency Janssen CF, Maiello P, Wright MJ, Kracinovsky KB, Newsome JT. Comparison of Atipamezole with Yohimbine for Antagonism of Xylazine in Mice Anesthetized with Ketamine and Xylazine. Journal of the American Association for Laboratory Animal Science. March 2017. PMID 28315642 · PMC5361038
18. Journal / agency Carruthers SG, Nelson M, Wexler HR, Stiller CR. Xylazine hydrochloridine (Rompun) overdose in man. Clinical Toxicology. October 1979. doi:10.3109/15563657908989878 · PMID 509891
19. Other Xylazine in Minnesota
20. Other The Growing Threat of Xylazine and its Mixture with Illicit Drugs
21. Other What is 'tranq' and why do police carry wound care kits because of it?. May 9, 2024
22. Journal / agency Hoffman GR, Giduturi C, Cordaro NJ, Yoshida CT, Schoffstall AM, Stabio ME, Zuckerman MD. Classics in Chemical Neuroscience: Xylazine. ACS Chemical Neuroscience. June 2024. doi:10.1021/acschemneuro.4c00172 · PMID 38747710
23. Journal / agency de Andrade Horn P, Berida TI, Parr LC, Bouchard JL, Jayakodiarachchi N, Schultz DC, Lindsley CW, Crowley ML. Classics in Chemical Neuroscience: Medetomidine. ACS Chemical Neuroscience. November 2024. doi:10.1021/acschemneuro.4c00583 · PMID 39405508 · PMC11587509
24. Journal / agency Angles JS, Zamboni LM, Sauer J, Fallico M, Dominguez-Gomez L, Delvecchio A, Helmy H, Reinicke S, Zaidi I, Okon B, Tuazon E, Cooper G, Linn-Walton R, Holtgrave DR. Emergence of Medetomidine in New York's Illicit Drug Supply. NEJM Evidence. May 2026. doi:10.1056/EVIDpha2600045 · PMID 41962141
25. Other Rose D. Seattle Police warn that base ingredient in 'zombie drug' tranq is being sold as standalone pill. April 7, 2024
26. Other Xylazine
27. Journal / agency Meyer GM, Maurer HH. Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC-MS, LC-MSn, and LC-HR-MSn. Analytical and Bioanalytical Chemistry. December 2013. doi:10.1007/s00216-013-7419-7 · PMID 24141317
28. Journal / agency Torruella RA. Xylazine (veterinary sedative) use in Puerto Rico. Substance Abuse Treatment, Prevention, and Policy. April 2011. doi:10.1186/1747-597x-6-7 · PMID 21481268 · PMC3080818
29. Other Melia M. ACLU probes prisoner deaths in Puerto Rico. 5 August 2010
30. Other A wave of homemade, synthetic drugs sweeps US and deepens crisis. 18 October 2026
31. Other Opioid Epidemic Updates: "Frankenstein Opioids" and Xylazine-Induced Skin Ulcers
32. Journal / agency Research Topics - Xylazine. 21 April 2022
33. Journal / agency Russell E, Sisco E, Thomson A, Lopes J, Rybak M, Burnett M, Heilman D, Appley MG, Gladden RM. Rapid Analysis of Drugs: A Pilot Surveillance System To Detect Changes in the Illicit Drug Supply To Guide Timely Harm Reduction Responses - Eight Syringe Services Programs, Maryland, November 2021-August 2022. MMWR. Morbidity and Mortality Weekly Report. April 2023. doi:10.15585/mmwr.mm7217a2 · PMID 37104171
34. Journal / agency Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, Shover C. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug and Alcohol Dependence. April 2022. doi:10.1016/j.drugalcdep.2022.109380 · PMID 35247724 · PMC9128597
35. Journal / agency Ehrman-Dupre R, Kaigh C, Salzman M, Haroz R, Peterson LK, Schmidt R. Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report. Journal of Addiction Medicine. 2022. doi:10.1097/ADM.0000000000000955 · PMID 35020700
36. Other Weixel N. White House says fentanyl laced with 'tranq' drug is 'emerging threat'. 2023-04-12
37. Journal / agency Rock KL, Lawson AJ, Duffy J, Mellor A, Treble R, Copeland CS. The first drug-related death associated with xylazine use in the UK and Europe. Journal of Forensic and Legal Medicine. July 2023. doi:10.1016/j.jflm.2023.102542 · PMID 37236142
38. Journal / agency Tranquilli WJ, Thurmon JC, Benson GJ, Davis LE. Alteration in the arrhythmogenic dose of epinephrine (ADE) following xylazine administration to halothane-anesthetized dogs. Journal of Veterinary Pharmacology and Therapeutics. June 1986. doi:10.1111/j.1365-2885.1986.tb00030.x · PMID 3723662
39. Journal / agency Tranquilli WJ, Thurmon JC, Benson GJ. Alterations in epinephrine-induced arrhythmogenesis after xylazine and subsequent yohimbine administration in isoflurane-anesthetized dogs. American Journal of Veterinary Research. July 1988. doi:10.2460/ajvr.1988.49.07.1072 · PMID 3421530
40. Journal / agency Celly CS, Atwal OS, McDonell WN, Black WD. Histopathologic alterations induced in the lungs of sheep by use of alpha2-adrenergic receptor agonists. American Journal of Veterinary Research. February 1999. doi:10.2460/ajvr.1999.60.02.154 · PMID 10048544
41. Journal / agency Celly CS, McDonell WN, Young SS, Black WD. The comparative hypoxaemic effect of four alpha 2 adrenoceptor agonists (xylazine, romifidine, detomidine and medetomidine) in sheep. Journal of Veterinary Pharmacology and Therapeutics. December 1997. doi:10.1046/j.1365-2885.1997.00097.x · PMID 9430770
42. Journal / agency Leblanc MM, Hubbell JA, Smith HC. The effects of xylazine hydrochloride on intrauterine pressure in the cow. Theriogenology. May 1984. doi:10.1016/0093-691X(84)90014-1 · PMID 16725917
43. Journal / agency Thurmon JC, Steffey EP, Zinkl JG, Woliner M, Howland D. Xylazine causes transient dose-related hyperglycemia and increased urine volumes in mares. American Journal of Veterinary Research. February 1984. doi:10.2460/ajvr.1984.45.02.224 · PMID 6711946
44. Journal / agency Hsu WH, Hummel SK. Xylazine-induced hyperglycemia in cattle: a possible involvement of alpha 2-adrenergic receptors regulating insulin release. Endocrinology. September 1981. doi:10.1210/endo-109-3-825 · PMID 6266810
45. Other Papich M. Saunders Handbook of Veterinary Drugs. 2016
46. Journal / agency Ball NS, Knable BM, Relich TA, Smathers AN, Gionfriddo MR, Nemecek BD, Montepara CA, Guarascio AJ, Covvey JR, Zimmerman DE. Xylazine poisoning: a systematic review. Clinical Toxicology. August 2022. doi:10.1080/15563650.2022.2063135 · PMID 35442125
47. Journal / agency Silva-Torres L, Veléz C, Alvarez L, Zayas B. Xylazine as a drug of abuse and its effects on the generation of reactive species and DNA damage on human umbilical vein endothelial cells. Journal of Toxicology. 2014. doi:10.1155/2014/492609 · PMID 25435874 · PMC4243599
48. Other Xylazine Public Health Advisory, November 2022
49. Journal / agency Scheinin H, Aantaa R, Anttila M, Hakola P, Helminen A, Karhuvaara S. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers. Anesthesiology. September 1998. doi:10.1097/00000542-199809000-00005 · PMID 9743392
50. Journal / agency Pertovaara A, Haapalinna A, Sirviö J, Virtanen R. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Reviews. 2005. doi:10.1111/j.1527-3458.2005.tb00047.x · PMID 16389294 · PMC6741735
51. Journal / agency Ndeereh DR, Mbithi PM, Kihurani DO. The reversal of xylazine hydrochloride by yohimbine and 4-aminopyridine in goats. Journal of the South African Veterinary Association. June 2001. doi:10.4102/jsava.v72i2.618 · PMID 11513261
52. Journal / agency Ayub S, Parnia S, Poddar K, Bachu AK, Sullivan A, Khan AM, Ahmed S, Jain L. Xylazine in the Opioid Epidemic: A Systematic Review of Case Reports and Clinical Implications. Cureus. March 2023. doi:10.7759/cureus.36864 · PMID 37009344 · PMC10063250
53. Journal / agency Hsu WH. Xylazine-induced depression and its antagonism by alpha adrenergic blocking agents. The Journal of Pharmacology and Experimental Therapeutics. July 1981. doi:10.1016/S0022-3565(25)32650-9 · PMID 6113279
54. Journal / agency Delehant TM, Denhart JW, Lloyd WE, Powell JD. Pharmacokinetics of xylazine, 2,6-dimethylaniline, and tolazoline in tissues from yearling cattle and milk from mature dairy cows after sedation with xylazine hydrochloride and reversal with tolazoline hydrochloride. Veterinary Therapeutics. 2003. PMID 14506588
55. Journal / agency Park JW, Chung HW, Lee EJ, Jung KH, Paik JY, Lee KH. α2-Adrenergic agonists including xylazine and dexmedetomidine inhibit norepinephrine transporter function in SK-N-SH cells. Neuroscience Letters. April 2013. doi:10.1016/j.neulet.2013.02.022 · PMID 23485735
56. Journal / agency Trinko JR, Foscue E, Kong EM, Basu A, Corstens AM, Thompson SL, Kaye AP, Taylor JR, DiLeone RJ. Xylazine induces dopamine release and augments the effects of fentanyl. The Journal of Clinical Investigation. November 2024. doi:10.1172/JCI183354 · PMID 39545408 · PMC11563672
57. Journal / agency Bedard ML, Huang XP, Murray JG, Nowlan AC, Conley SY, Mott SE, Loyack SJ, Cline CA, Clodfelter CG, Dasgupta N, Krumm B, Roth BL, McElligott ZA. Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism. Addiction Neuroscience. June 2024. doi:10.1016/j.addicn.2024.100155 · PMID 39086495 · PMC11290297
58. Journal / agency Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. Journal of the American Association for Laboratory Animal Science. September 2013. PMID 24041212 · PMC3784662
59. Journal / agency Barroso M, Gallardo E, Margalho C, Devesa N, Pimentel J, Vieira DN. Solid-phase extraction and gas chromatographic- mass spectrometric determination of the veterinary drug xylazine in human blood. Journal of Analytical Toxicology. April 2007. doi:10.1093/jat/31.3.165 · PMID 17579964
60. Other Britain working at pace to curb rising synthetic drugs threat
61. Other The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2024 and The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment) (No. 2) Regulations 2024

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.